• Citer

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

par Fizazi, Karim;Lipton, Allan;Mariette, Xavier;Body, Jean-Jacques ;Rahim, Yasmin;Gralow, Julie R;Gao, Guozhi M.;Wu, Ling;Sohn, Winnie;Jun, Susie
Référence Journal of clinical oncology, 27, 10, page (1564-1571)
Publication Publié, 2009-04

Article révisé par les pairs

• Détails
• Contenu

Résumé :

Patients with bone metastases and elevated urinary N-telopeptide (uNTx), representing excessive bone resorption, are at increased risk for skeletal-related events (SREs), cancer progression, and death. Osteoclast-mediated bone resorption is regulated by RANKL. We evaluated the effect of denosumab, a fully human monoclonal antibody against RANKL, in patients with bone metastases and elevated uNTx levels despite ongoing intravenous (IV) bisphosphonate (BP) therapy.